{"id":"vaccine-for-intramuscular-injection","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine contains a weakened or inactivated form of the target pathogen, which triggers an immune response without causing the disease. This immune response is then stored in the body's immune memory, allowing it to recognize and fight the pathogen if it enters the body in the future.","oneSentence":"This vaccine stimulates the body's immune system to produce a specific response against the target pathogen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:13.694Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19"}]},"trialDetails":[{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT06585241","phase":"PHASE4","title":"A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-09","conditions":"SARS-CoV-2","enrollment":1144},{"nctId":"NCT05988203","phase":"PHASE1, PHASE2","title":"A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-09-21","conditions":"Monkeypox","enrollment":96},{"nctId":"NCT07407569","phase":"PHASE2","title":"Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2026-03-25","conditions":"Human Papilloma Virus Infection Type 16","enrollment":50},{"nctId":"NCT07221162","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-05","conditions":"COVID-19","enrollment":140},{"nctId":"NCT05703607","phase":"PHASE1, PHASE2","title":"A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-01-25","conditions":"Shingles, Herpes Zoster Infection, Human","enrollment":485},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT07492303","phase":"PHASE1","title":"A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-04-20","conditions":"Pertussis (Whooping Cough), Diphtheria, Tetanus","enrollment":96},{"nctId":"NCT06833073","phase":"PHASE2","title":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-11","conditions":"Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ","enrollment":308},{"nctId":"NCT07300085","phase":"PHASE1","title":"A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-11-08","conditions":"Healthy Participants","enrollment":100},{"nctId":"NCT03568058","phase":"PHASE1","title":"Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers","status":"COMPLETED","sponsor":"Aaron Miller","startDate":"2018-07-26","conditions":"Advanced Cancer","enrollment":25},{"nctId":"NCT07478952","phase":"PHASE1","title":"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-17","conditions":"Epstein-Barr Virus","enrollment":120},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT05766904","phase":"PHASE3","title":"Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-04","conditions":"Gonorrhea, Sexually Transmitted Infection","enrollment":150},{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT07467707","phase":"PHASE3","title":"An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults","status":"NOT_YET_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2026-05","conditions":"Chikungunya Virus","enrollment":6144},{"nctId":"NCT02886065","phase":"PHASE1","title":"A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-03-07","conditions":"Smoldering Multiple Myeloma","enrollment":19},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT06134648","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-11-01","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus","enrollment":646},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06760208","phase":"","title":"A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-13","conditions":"Pneumococcal Immunization, Safety","enrollment":660},{"nctId":"NCT06177912","phase":"PHASE3","title":"A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-18","conditions":"Pneumococcal Infection","enrollment":882},{"nctId":"NCT05743595","phase":"PHASE1","title":"Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-10-27","conditions":"Unmethylated Glioblastoma","enrollment":27},{"nctId":"NCT06253533","phase":"PHASE1","title":"ICVAX as a HIV Therapeutic DNA Vaccine","status":"COMPLETED","sponsor":"Immuno Cure Holding (HK) Limited","startDate":"2023-02-14","conditions":"Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection","enrollment":45},{"nctId":"NCT05580458","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-13","conditions":"Herpes Zoster","enrollment":225},{"nctId":"NCT07454915","phase":"PHASE2","title":"PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia","status":"NOT_YET_RECRUITING","sponsor":"PapiVax Biotech, Inc.","startDate":"2026-03-01","conditions":"Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16","enrollment":138},{"nctId":"NCT06508138","phase":"PHASE1","title":"Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection","status":"ENROLLING_BY_INVITATION","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-18","conditions":"HPV 16 Infection, HPV-Related Carcinoma, Recurrence","enrollment":24},{"nctId":"NCT06485258","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2024-08-06","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT07252791","phase":"PHASE4","title":"Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-16","conditions":"Autoimmune Rheumatologic Disease","enrollment":114},{"nctId":"NCT07379580","phase":"PHASE2","title":"A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-20","conditions":"Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection","enrollment":310},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT06975878","phase":"PHASE3","title":"Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":1092},{"nctId":"NCT07443709","phase":"PHASE2","title":"Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Oriol Manuel","startDate":"2026-04","conditions":"Zoster; Herpes","enrollment":75},{"nctId":"NCT04915768","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-23","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT04006457","phase":"PHASE3","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Alopecia Areata","enrollment":1052},{"nctId":"NCT07417488","phase":"PHASE1","title":"GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas","status":"NOT_YET_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2026-02","conditions":"Colorectal Cancer, Small Bowel Adenocarcinoma","enrollment":18},{"nctId":"NCT06592794","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-24","conditions":"Acute Gastroenteritis, Norovirus Acute Gastroenteritis","enrollment":37864},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT03512249","phase":"PHASE2","title":"Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence","status":"COMPLETED","sponsor":"International AIDS Vaccine Initiative","startDate":"2019-01-31","conditions":"Tuberculosis, Pulmonary","enrollment":831},{"nctId":"NCT05334706","phase":"PHASE4","title":"A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)","status":"RECRUITING","sponsor":"Miquel Angel Pavon Ribas","startDate":"2022-09-13","conditions":"Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV","enrollment":69},{"nctId":"NCT01086904","phase":"PHASE2","title":"Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Renal Transplant Recipients, Immunosuppression","enrollment":122},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT05938387","phase":"PHASE1","title":"Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma","status":"COMPLETED","sponsor":"CureVac","startDate":"2023-06-01","conditions":"Glioblastoma","enrollment":37},{"nctId":"NCT06793826","phase":"","title":"Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-17","conditions":"Hepatitis B, Haemophilus Influenzae Type b Immunisation","enrollment":713},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT07409805","phase":"PHASE1","title":"YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-01","conditions":"Colorectal Cancer","enrollment":9},{"nctId":"NCT07303751","phase":"PHASE2","title":"Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV","status":"NOT_YET_RECRUITING","sponsor":"Institut d'Investigació Biomèdica de Bellvitge","startDate":"2026-02-01","conditions":"HPV, High-risk HPV (Any Strain), Human Papillomavirus (HPV) Infections","enrollment":80},{"nctId":"NCT04127786","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-21","conditions":"Rabies, Healthy Volunteers","enrollment":1708},{"nctId":"NCT07282795","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-03-31","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":670},{"nctId":"NCT05286060","phase":"PHASE2","title":"Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2022-03-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":56},{"nctId":"NCT05423418","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2022-09-08","conditions":"Human Immunodeficiency Virus (HIV), AIDS Virus","enrollment":65},{"nctId":"NCT07095231","phase":"PHASE1","title":"Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-08-11","conditions":"COVID-19","enrollment":60},{"nctId":"NCT07237282","phase":"PHASE1","title":"A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-03-01","conditions":"Hepatitis C","enrollment":27},{"nctId":"NCT06143046","phase":"PHASE2","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-11-15","conditions":"Respiratory Syncytial Virus","enrollment":360},{"nctId":"NCT06546800","phase":"","title":"SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-05-27","conditions":"Respiratory Syncytial Virus Infection","enrollment":1100},{"nctId":"NCT06634797","phase":"PHASE4","title":"A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-10-08","conditions":"Healthy Volunteers","enrollment":1000},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05500417","phase":"PHASE1","title":"Safety and Immunogenicity of CJCV2 With and Without ALFQ","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-09-13","conditions":"Campylobacter Infection","enrollment":59},{"nctId":"NCT07019883","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-06-12","conditions":"Avian Influenza","enrollment":80},{"nctId":"NCT02405221","phase":"PHASE1","title":"Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-04-04","conditions":"HPV16 Associated Cervical Cancer","enrollment":15},{"nctId":"NCT04607408","phase":"PHASE1","title":"Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2020-11-10","conditions":"HIV Infections","enrollment":38},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT07373301","phase":"PHASE2","title":"Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia","status":"NOT_YET_RECRUITING","sponsor":"Malaria Vaccine and Drug Development Center","startDate":"2026-01-19","conditions":"Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention","enrollment":72},{"nctId":"NCT04985760","phase":"PHASE1","title":"Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy","status":"COMPLETED","sponsor":"Madhu Chhanda Choudhary","startDate":"2021-09-30","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT06604767","phase":"PHASE1","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-09-17","conditions":"Respiratory Syncytial Virus Infection, Metapneumovirus Infection, Parainfluenzae Virus Infection","enrollment":390},{"nctId":"NCT07185399","phase":"PHASE4","title":"Systems Biological Analysis of Immune Responses to RSV Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2025-10-13","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":14},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06727058","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-09","conditions":"Influenza Immunization","enrollment":276},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT04869592","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2021-04-25","conditions":"COVID-19","enrollment":3100},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT07342257","phase":"PHASE1","title":"SYN023 With Rabies Vaccine in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2024-11-30","conditions":"Rabies Post-exposure Prophylaxis","enrollment":108},{"nctId":"NCT07345208","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of ID vs IM Rabies Vaccine","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-12-15","conditions":"Rabies","enrollment":90},{"nctId":"NCT06128733","phase":"PHASE1, PHASE2","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-10-31","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1215},{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-11-08","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":383},{"nctId":"NCT06932523","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-04-04","conditions":"Herpes Zoster (HZ)","enrollment":645},{"nctId":"NCT07324304","phase":"PHASE2","title":"NWRD06 DNA Plasmid for HCC After Curative Resection.","status":"RECRUITING","sponsor":"Newish Technology (Beijing) Co., Ltd.","startDate":"2025-12-08","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":30},{"nctId":"NCT06132789","phase":"PHASE1","title":"A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-11-27","conditions":"Rabies","enrollment":80},{"nctId":"NCT07133178","phase":"PHASE3","title":"A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2026-02-06","conditions":"Chikungunya Virus Infection","enrollment":""},{"nctId":"NCT04544267","phase":"PHASE3","title":"Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-15","conditions":"Influenza","enrollment":100},{"nctId":"NCT05182125","phase":"PHASE1","title":"Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2021-11-25","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT06680128","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2025-02-24","conditions":"Japanese Encephalitis Virus Disease","enrollment":402},{"nctId":"NCT05537038","phase":"PHASE1","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-04-18","conditions":"Tuberculosis","enrollment":120},{"nctId":"NCT07295028","phase":"PHASE1","title":"Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults","status":"RECRUITING","sponsor":"Vicebio Australia Proprietary Limited","startDate":"2025-11-17","conditions":"Lower Respiratory Tract Disease, Healthy Participants","enrollment":240},{"nctId":"NCT07275645","phase":"PHASE3","title":"A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years","status":"NOT_YET_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-12-18","conditions":"Rabies","enrollment":3000},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT06756269","phase":"PHASE2","title":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","status":"RECRUITING","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2025-01-15","conditions":"HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia","enrollment":330},{"nctId":"NCT03878121","phase":"PHASE1","title":"Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-17","conditions":"Healthy Volunteer","enrollment":300},{"nctId":"NCT05575492","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-11-07","conditions":"Cytomegalovirus","enrollment":873},{"nctId":"NCT02723773","phase":"PHASE3","title":"A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-04-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":7539},{"nctId":"NCT04684914","phase":"PHASE2","title":"HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Altimmune, Inc.","startDate":"2020-12-26","conditions":"Hepatitis B, Chronic","enrollment":87},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1738,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vaccine for intramuscular injection","genericName":"Vaccine for intramuscular injection","companyName":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","companyId":"chumakov-federal-scientific-center-for-research-and-development-of-immune-and-bi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the body's immune system to produce a specific response against the target pathogen. Used for Prevention of COVID-19.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}